Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric ...
Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with ...
In addition, the Company closed its previously announced concurrent private placement with funds affiliated with Leavitt Equity Partners for the purchase and sale of 267,686 shares of common stock and ...
Allurion Technologies Inc. is cleared by regulators in France to resume sales of its swallowable gastric balloon to treat ...
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the ...
Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in two upcoming investor conferences.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
NATICK, Mass., February 20, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity ...
NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a ...